Preparation and characterization of polysaccharide-based nanoparticles with anticoagulant activity

International Journal of Nanomedicine (Impact Factor: 4.38). 01/2012; 7:2975-2986.


The aim of this study was to produce and characterize nanoparticles (NPs), combining chondroitin sulfate (CS) and fucoidan (FC) with chitosan for therapeutic purposes. These NPs were characterized by dynamic light scattering, zeta potential determination, and transmission electronic microscopy. The anticoagulant activity was determined for FC NPs and compared with FC solution at the same concentration. FC NPs showed regular shapes and better anticoagulant activity than free polysaccharide solution. FC solution did not affect coagulation compared to FC NPs, which increased up to two-fold, even at a lower concentration. Cytotoxicity and perme-ability tests were conducted using Caco-2 cell monolayer, exhibiting no toxic effect in this cell line and higher permeability for NP2 samples than FC solution at the same concentration.

Download full-text


Available from: Lucio Cabral
  • Source
    • "The figures were adopted and redrawn from[172].[167,168]2 Fucoidan lipid NPs Chemical modification 100 nm[169]3 Fucoidan nanogels Graft with hexadecylamine 123 nm[170]4 Chitosan-fucoidan Coacervation process 154 and 453 nm[173]5 Fucoidan-coated poly(isobutylcyanoacrylate) NPs Anionic emulsion polymerization 193 ˘ 4 nm to 399 ˘ 0.7 nm[174]6.2. Fucoidan NPs for Growth Factor Delivery A diverse set of fucoidan NPs for the delivery of growth factors has been reported (Table 7). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, there have been major advances and increasing amounts of research on the utilization of natural polymeric materials as drug delivery vehicles due to their biocompatibility and biodegradability. Seaweed polysaccharides are abundant resources and have been extensively studied for several biological, biomedical, and functional food applications. The exploration of seaweed polysaccharides for drug delivery applications is still in its infancy. Alginate, carrageenan, fucoidan, ulvan, and laminarin are polysaccharides commonly isolated from seaweed. These natural polymers can be converted into nanoparticles (NPs) by different types of methods, such as ionic gelation, emulsion, and polyelectrolyte complexing. Ionic gelation and polyelectrolyte complexing are commonly employed by adding cationic molecules to these anionic polymers to produce NPs of a desired shape, size, and charge. In the present review, we have discussed the preparation of seaweed polysaccharide-based NPs using different types of methods as well as their usage as carriers for the delivery of various therapeutic molecules (e.g., proteins, peptides, anti-cancer drugs, and antibiotics). Seaweed polysaccharide-based NPs exhibit suitable particle size, high drug encapsulation, and sustained drug release with high biocompatibility, thereby demonstrating their high potential for safe and efficient drug delivery.
    Full-text · Article · Jan 2016 · Polymers
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review article is to explore the utilization of biodegradable polymers and their associated physicochemical properties in nano drug delivery (NDD). The main hub of the pharma industry is involved in the development of innovative biodegradable and biocompatible polymers which have targeting ability and a predictable release profile of an incorporated active pharmaceutical ingredient (API) or therapeutic agents. Moreover, the pharmaceutical and biological efficiency of the nano drug delivery system varies with the inherent properties of the polymer. The foremost, important physicochemical properties of biodegradable polymers include molecular weight, hydrophobicity, surface charge, crystallinity, composition of the co-polymer, glass transition temperature, and the nature of coating material. Nevertheless, these properties can be manipulated to modify the kinetics of the delivery system by selecting an optimum polymer (based on physicochemical properties) for a specific purpose.
    Full-text · Article · Oct 2013 · Polymer Reviews
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Cardiovascular diseases are the most frequent cause of morbidity and mortality worldwide. Among the most important cardiovascular diseases are atherothrombosis and venous thromboembolism that present platelet aggregation as a key event. Currently, the commercial antiplatelet agents display several undesirable effects, which prompt the search for new compounds with better therapeutic index, more efficient body distribution and mechanism. Methods: In this work we characterized in vivo and in vitro the antithrombotic and toxicological profiles of novel antiplatelet N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides derivatives also comparing them with aspirin. In addition we also analyzed the stability of the more active compound after encapsulation in PLGA or PCL nanoparticles and the release profile of these new nanosystems. Results: The biological results revealed not only the selective effect against arachidonic acid-induced platelet aggregation mainly for compounds 2c, 2e and 2h but also their in vivo active profile on thromboembolism pulmonary animal model with better survival rates (e.g. 82%) than aspirin (33%). The overall toxicological profile was determined by in vitro (MTT reduction tests, neutral red uptake in kidney VERO cells and hemolysis assays) and in vivo (pulmonary embolism) assays that pointed 2c as the most promising derivative with potential as a lead compound. By using the nanoprecipitation technique 2c was loaded into PLGA and PCL nanoparticles showing controlled release profile over 21days according to our drug release tests. Conclusion: According to our results compound 2c is the most interesting derivative for further studies as it showed the best activity and toxicological profile also allowing the nanoencapsulation process. Thus 2c may assist in determining a new potential therapy with favorable pharmacokinetics for treatment of thrombotic disorders.
    Full-text · Article · May 2014 · Thrombosis Research
Show more